-
October 16, 2019
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
-
September 28, 2019
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
-
September 24, 2019
Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology
-
September 9, 2019
Aileron Therapeutics Announces Management Change
-
September 3, 2019
Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York
-
August 6, 2019
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
-
July 30, 2019
Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
-
July 30, 2019
Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019
-
June 27, 2019
Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
-
June 24, 2019
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach